Inhaltsseite: Home

Research insight and rising markets

Thursday, 15 July 2021 Reading time : 1 minute

Our in-house research team - ZKB Equity Research - regularly provides valuable assessments of expected developments on the markets. If the research team rates a stock as "overweight", this means that it expects outperformance. Investors who want to participate in these developments and at the same time appreciate the features of products with barriers can benefit from attractive yield enhancement products.

All shares of the following (Callable) Barrier Reverse Convertible are rated "overweight" by ZKB Equity Research.

Barrier Reverse Convertible on Nestlé, Zurich, Novartis, Roche and Swisscom (CHF)

  • 7.5%* Coupon p.a. (15% Total)
  • 69%* Barrier
  • 2 years Term
  • Subscription period until 22.07.2021
  • Termsheet

Barrier Reverse Convertible on Clariant, Givaudan, Holcim and Sika (CHF)

  • 8%* Coupon p.a.
  • 70%* Barrier
  • 1 year Maturity
  • Subscription period until 21.07.2021
  • Termsheet

 

Callable BRC on Nestlé, Novartis, Roche, Zurich and Givaudan (CHF)

  • 10%* Coupon p.a.
  • 74%* Barrier
  • 1 year Term
  • Subscription period until 20.07.2021
  • Termsheet

A good way to profit from markets that continue to recover rapidly is to invest in the respective leading indices. These can be seen as a proxy for the respective economies - if these are on a good course, share prices usually follow upwards as well.

Callable BRC on SMI®, Euro Stoxx 50® and S&P500®

  • 5%* Coupon p.a.
  • 71%* Barrier
  • 15 months Term
  • Subscription period until 21.07.2021
  • Termsheet
  • 4%* Coupon p.a.
  • 61%* Barrier
  • 12 months Maturity
  • Subscription period until 22.07.2021
  • Termsheet
*indicative
Advanced search
/home/search/guidepost.html /home/general/quick_search_live.html

Current products

Ajax loading